Amylin Pharmaceuticals, Inc.

Other

Timothy J Rink

Andrew A Young

Orville G Kolterman

Kathleen Ann Keating Brown

Kathryn Susan Prickett

Kevin Beaumont

Garth J Cooper

Nigel R Beeley

Kathleen Ann Brown

Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are also described.

Methods for regulating postprandial blood glucose

Methods for regulating gastrointestinal motility

Novel methods for use in identifying or assaying compounds which can simulate the ability of amylin to cause hyperlactemia and hyperglycemia in in vivo biological models, or for use in evaluating the potency of compounds known or suspected to simulate these actions of amylin, which involve introducing test samples into in vivo test systems and determining the presence or amount of a rise in lactate, or determining the presence or amount of a rise in lactate and a rise in glucose, following test sample administration.

Amylin activity assays

Method and compositions for treating a mammal by administering to that mammal an insulin (having the in vitro activity of stimulating glucose incorporation into glycogen in rat soleus muscle) and an amylin (having the in vitro activity of suppressing glucose incorporation into glycogen in rat soleus muscle) using specific molar ratios of an insulin to an amylin.

Method and composition for treatment of insulin requiring mammals

Compositions and methods for reducing food intake, suppressing appetite and controlling body weight are provided. Such compositions may include an amylin agonist and a CCK agonist or a hybrid peptide.

Appetite regulating compositions

Treatment of anorexia and related states

Methods for treating conditions associated with elevated, inappropriate or undesired renin activity are disclosed which comprise administration of an effective amount of any amylin antagonist alone or in conjunction with other anti-hypertensive agents. Methods for screening for and/or evaluating anti-renin amylin antagonists are also described.

Methods for treating renin-related disorders with amylin antagonists

Methods for identifying or screening or characterizing or assaying or isolating known or candidate agonists and antagonists of amylin, comprising binding assays utilizing preparations containing specific receptors for amylin. Membranes from the brain that contain high density receptors for amylin are particularly useful for the methods of this invention, and as a source of amylin receptors.

Growing community of inventors

La Jolla, CA, United States of America

Timothy J Rink